Kyverna Therapeutics, Inc.
KYTXNasdaqCIK 1994702HealthcareFiscal year ends Dec 31
Reports and events: 58 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2410:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-400062 |
| 2026-08-1120:07 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-344607 |
| 2026-08-1120:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344572 |
| 2026-07-2712:00 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-316916 |
| 2026-07-0910:00 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-298979 |
| 2026-06-0220:30 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-253604 |
| 2026-05-1812:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-227920 |
| 2026-05-1220:08 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-219397 |
| 2026-05-1220:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219377 |
| 2026-05-0412:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-202610 |
| 2026-04-2211:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-168287 |
| 2026-04-2222:45 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-167512 |
| 2026-04-2012:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-162755 |
| 2026-04-1320:02 ET | DEF 14A | Proxy statementPeriod 2026-05-27 | 0001193125-26-152835 |
| 2026-03-2620:11 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-126242 |
| 2026-03-2620:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-126216 |
| 2026-02-2413:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-065320 |
| 2026-02-0313:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-034464 |
| 2026-01-1213:00 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-009810 |
| 2025-12-1802:50 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-123033 |
| 2025-12-1513:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-318469 |
| 2025-12-1511:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-318377 |
| 2025-11-1221:11 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-277584 |
| 2025-11-1221:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277569 |
| 2025-11-0313:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-261719 |
| 2025-10-2912:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-254698 |
| 2025-10-2910:32 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-254571 |
| 2025-09-2520:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-217434 |
| 2025-08-1220:11 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-107321 |
| 2025-08-1220:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-107300 |
| 2025-06-3013:01 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-25-059289 |
| 2025-06-0320:03 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-080896 |
| 2025-05-1320:08 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-070325 |
| 2025-05-1320:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-070286 |
| 2025-04-1420:03 ET | DEF 14A | Proxy statementPeriod 2025-05-29 | 0000950170-25-053699 |
| 2025-03-2720:58 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-25-046176 |
| 2025-03-2720:12 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-046074 |
| 2025-03-2720:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-046052 |
| 2025-01-2121:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-007220 |
| 2025-01-1312:35 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-002831 |
| 2024-11-2621:40 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-131074 |
| 2024-11-1321:24 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-126366 |
| 2024-11-1321:16 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-126342 |
| 2024-10-2112:00 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-089095 |
| 2024-09-1612:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-24-078736 |
| 2024-08-1220:18 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-095462 |
| 2024-08-1220:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095433 |
| 2024-07-1520:11 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-083570 |
| 2024-06-1410:12 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-073312 |
| 2024-05-1420:29 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-059628 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.